Our findings are consistent with a systematic review and meta-analysis of 17 studies on the behavioral impact of genetic testing for complex diseases that reported significant increases in self-reported behavior change after providing results among risk variant carriers compared with non-carriers (30), and with results from our randomized controlled trial among non-Hispanic White individuals with limited melanoma risk phenotypes that found MC1R precision prevention materials improved some melanoma prevention activities (31). Here, MC1R is linked to melanoma.